Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Articles by Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Next Steps in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

March 2nd 2021

MRD Assessment in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

March 2nd 2021

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

March 2nd 2021

MCL: Emerging BTKi-Combination Approaches

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 23rd 2021

Emerging BTK Inhibitors in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 23rd 2021

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 16th 2021

Venetoclax in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 16th 2021

BTK Inhibitors for Relapsed MCL: Important Considerations

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 9th 2021

Selecting a BTKi for Relapsed MCL Treatment

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 9th 2021

Acalabrutinib and Zanubrutinib for Relapsed MCL

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

February 2nd 2021

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 26th 2021

Treatment Approaches in Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

ByJohn P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine,Krish Patel, MD, Swedish Medical Center,Tycel Jovelle Phillips, MD, University of Michigan,Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

January 19th 2021

Latest Updated Articles

Selecting a BTKi for Relapsed MCL Treatment
February 9th 2021
Lenalidomide and Bortezomib for Mantle Cell Lymphoma
January 26th 2021
BTK Inhibitors for Relapsed MCL: Important Considerations
February 9th 2021
Emerging BTK Inhibitors in Mantle Cell Lymphoma
February 23rd 2021
Novel Therapies in the Pipeline in Mantle Cell Lymphoma
March 2nd 2021
CAR T-Cell Therapy for R/R Mantle Cell Lymphoma
February 16th 2021

Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Articles by Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Next Steps in Mantle Cell Lymphoma

MRD Assessment in Mantle Cell Lymphoma

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

MCL: Emerging BTKi-Combination Approaches

Emerging BTK Inhibitors in Mantle Cell Lymphoma

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

Venetoclax in Mantle Cell Lymphoma

BTK Inhibitors for Relapsed MCL: Important Considerations

Selecting a BTKi for Relapsed MCL Treatment

Acalabrutinib and Zanubrutinib for Relapsed MCL

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

Go-To Treatment Regimens in Mantle Cell Lymphoma

Treatment Approaches in Mantle Cell Lymphoma

Accurately Diagnosing Mantle Cell Lymphoma

Latest Updated Articles

Trending on OncLive

Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma

Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC

Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)

Data Point to Pirtobrutinib-Based Regimens as a New SOC Option for R/R CLL

Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC